How does FDA compare to other global regulatory agencies when it comes to virtual inspections? What alternatives to in-person inspections have pharmaceutical companies experienced? And how do FDA investigators adhere to state-level COVID-19 restrictions when onsite inspections do occur?

Last December, talks at the FDLI Enforcement, Litigation, and Compliance Conference addressed these questions and more. Redica Systems Senior GMP Quality Expert Jerry Chapman covered these talks in three Conference Spotlight articles.

FDA Inspections During Covid Articles:

[Related: For more on virtual inspections from Jerry Chapman, download his 2020 report that includes a look at an innovative technology that drew praise from an EMA inspector.]

Virtual inspections report banner

Get a Demo

We’ll can show you insights into any of your key suppliers, FDA investigators, inspection trends, and much more.

Request a Demo